؉ T-cell responses play a pivotal role in anti-human immunodeficiency virus (HIV) immunity and the control of viremia. The rhesus macaque is an important animal model for HIV-related research. Among the MHC I alleles of the rhesus macaque, Mamu-A*02 is prevalent, presenting in >20% of macaques. In this study, we determined the crystal structure of Mamu-A*02, the second structure-determined MHC I from the rhesus macaque after Mamu-A*01. The peptide presentation characteristics of Mamu-A*02 are exhibited in complex structures with two typical Mamu-A*02-restricted CD8
Since the identification of human immunodeficiency virus (HIV) as the etiological agent of AIDS in the 1980s, the ultimate goal of immunological research in this field has been the development of an efficient vaccine against HIV (20, 28) . However, no successful vaccine has ever been developed for clinical application, and unfortunately, the epidemiological outlook for AIDS is not optimistic (29) . There are 33 million people worldwide living with HIV/AIDS, with 2.7 million new infections every year (http://www.who.int/hiv/data/en/index.html). Nonetheless, thanks to novel strategies and techniques for vaccine development, several potential HIV vaccines have been reported in preclinical studies with humans or nonhuman primate models (25, 35, 55) .
Cytotoxic T lymphocyte (CTL)-mediated immunity plays a pivotal role in the immune response to HIV and in transient clearance of the virus in the peripheral blood (5, 31, 58) . Recent studies demonstrate that specific CD8 ϩ T-cell responses are induced at a very early stage of HIV infection and contribute to the control of acute viremia (23) . Conventionally developed vaccines for HIV, which mainly induce humoral immunity, cannot protect the host from infection, due to the rapid escape of B-cell epitopes. Thus, in the last decade, systematic studies have focused on the interaction between HIV and cellular immunity, aiming to develop efficient T-cell-based vaccines (57, 58, 60) . Clearly, an ideal scenario would be a vaccine that stimulates both humoral and cellular immunities against HIV.
The animal model most commonly used for HIV-related studies is the Indian rhesus macaque (7, 26, 61) . The rhesus macaque model has several important assets: rhesus macaques can be infected with simian immunodeficiency virus (SIV), which has the highest genetic similarity to HIV, develop an HIV infection-like disease with acute to chronic infections, and can ultimately develop an AIDS-like disease (21) ; rhesus macaques have a genetic background similar to that of humans (61) ; and many cardinal immune molecules, such as major histocompatibility complexes (MHCs), which are irreplaceable factors in anti-HIV immunity in humans, are also found in rhesus macaques (10, 16, 78) . The MHC class I (MHC I) molecules of rhesus macaques have been thoroughly sequenced genetically, indicating their close relationship with susceptibility and the pathogenesis of SIV infection (27, 48, 62) . Rhesus macaque MHC I Mamu-A*02 is one of the most prevalent MHC alleles in Indian rhesus macaques, representing approximately 20% of the entire MHC I population. In contrast to SIV-infected Mamu-A*01 ϩ monkeys, which are long-term nonprogressors (LTNP) (39, 48, 49, 53, 76) , SIVinfected monkeys carrying Mamu-A*02 are intermediate progressors (4, 40, 62) with moderate resistance to SIV infection.
In terms of T-cell-mediated immunity, Ͼ20 CD8 ϩ T-cell epitopes with Mamu-A*02 restriction have been identified thus far (40, 59, 72, 74) . Peptide YY9 (YTSGPGIRY) and GY9 (GSENLKSLY), derived from the SIV Nef and Gag proteins, respectively, are two of the earliest-defined typical Mamu-A*02-restricted epitopes, which are commonly used in SIV-specific T-cell immunity studies of the rhesus macaque (40, 59, 72) . Specific T-cell responses against these two epitopes in Mamu-A*02 rhesus macaques can be detected at an early stage after SIV infection or after inoculation with Gag and Nef protein expression vaccines (43, 47, 58) . Furthermore, SIV replication is efficiently suppressed in vitro by YY9-and GY9-stimulated CD8 ϩ T cells, which may indicate a major role of T lymphocytes in reducing peak viremia and maintaining viral control in the chronic phase of the infection (15, 39, 73) .
Nevertheless, it has been demonstrated that immunodominant CTL responses can lead to the selection of escape variants of SIV. Special escape variants for peptide YY9 in rhesus macaques during acute SIV infection have been thoroughly studied (9, 19, 47, 51, 52, 72) . However, in the absence of selective pressure, the mutant epitope of YY9 can continue to evolve and revert to the original sequence, confirming the significant role of CTLs in anti-SIV immunity (19) . Interestingly, thus far, no escape variants have been detected for peptide GY9, even though GY9 also efficiently suppresses viral replication (39, 72) . Thus, the Mamu-A*02 ϩ rhesus macaque is an appropriate model in which to study the association of SIV with corresponding antivirus cellular immunity, especially in a GY9 and YY9 epitope-specific manner.
Generally, the characteristics of CTL epitope presentation by MHC molecules have crucial impacts on the immunogenicity of the peptides (34, 70, 71) . Determination of the structures of MHC I molecules complexed with restricted peptides has made it possible for immunologists to "observe" the presentation of the CTL epitopes by MHCs (3, 12, 22) . In our previous work, we described the first structure of a nonhuman primate MHC class I molecule, Mamu-A*01 (13) . Here we determined the crystal structures of another prevalent rhesus macaque MHC allele, Mamu-A*02, complexed with the two typical Mamu-A*02-restricted epitopes YY9 and GY9. The distinct presentation of these two peptides by Mamu-A*02 in our crystal structures explains the diverse peptide binding properties of Mamu-A*02 and the appearance of the YY9 escape mutants.
MATERIALS AND METHODS
Peptide synthesis and preparation of expression constructs. Peptides YY9 (Nef residues 159 to 167; YTSGPGIRY) and GY9 (Gag residues 71 to 79; GSENLKSLY) were synthesized with ϳ90% purity as determined by reversephase high-performance liquid chromatography (HPLC) (Scilight-Peptide Inc., Beijing, China). The peptides were stored at Ϫ80°C as freeze-dried powders and were dissolved in dimethyl sulfoxide (DMSO) before use. The cDNA of Mamu-A*02 was a gift from David I. Watkins of the Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison. The expression plasmids for the extracellular domain (residues 1 to 276) of Mamu-A*02 and human or rhesus macaque ␤ 2 -microglobulins (␤ 2 m) (residues 1 to 99) were constructed previously in our laboratory (18, 75) .
Expression and purification of rhesus macaque MHC I Mamu-A*02 complexes. All proteins were expressed as inclusion bodies in Escherichia coli strain BL21(DE3) and were solubilized in 8 M urea buffers using previously described protocols (36, 68) . The Mamu-A*02/YY9 complex was renatured from inclusion bodies of the Mamu-A*02 heavy chain and rhesus ␤ 2 m in the presence of peptide YY9 by the dilution-refolding method, as described previously (13) . Briefly, for dilution-refolding, the Mamu-A*02 heavy chain, ␤ 2 m, and the peptide (in a 1:1:3 molar ratio) were refolded by dilution in a 400 mM Arg ⅐ HCl solution. After 24 h of incubation at 277 K, the soluble portion was concentrated, and the solution was changed to 20 mM Tris ⅐ HCl and 50 mM NaCl. The proteins were then further purified through gel filtration on HiLoad 16/60 Superdex 75 and Resource Q ion-exchange columns (GE Healthcare, Sweden). Mamu-A*02/GY9 was produced by the Mamu-A*02 heavy chain, human ␤ 2 m, and peptide GY9 by the same procedures (13) .
Crystallization and data collection. Crystallization trials were performed via the hanging-drop diffusion method using Crystal Screen kit I/II and the Index screen (Hampton Research). The Mamu-A*02/YY9 crystals were obtained in a 0.1 M Bis-Tris (pH 5.5)-2.0 M ammonium sulfate solution at 291 K with a protein concentration of 15 mg/ml. Single crystals of Mamu-A*02/GY9 grew in 0.1 M Tris-HCl (pH 5.5), 0.12 M ammonium sulfate, and 38% polyethylene glycol monomethyl ether 20,000 at the same temperature and concentration.
Data from the Mamu-A*02 complexes were collected in-house on a Rigaku MM007 rotating-anode X-ray generator at 40 kV and 20 mA (Cu K␣; ϭ 1.5418 Å). The crystals were soaked for 10 to 60 seconds in a reservoir solution supplemented with 20 to 30% glycerol as a cryoprotectant. The diffraction data of these crystals were collected at 100 K and were processed utilizing the HKL2000 program (54) .
Structure determination and analysis. The structure of Mamu-A*02/YY9 was determined by molecular replacement using Mamu-A*01 (Protein Data Bank [PDB] code 1ZVS) (13) as a search model in the Crystallography & NMR System (CNS) program (6) . Clear solutions in both the rotation and translation functions correspond to three molecules in one asymmetric unit. The residues that were different in Mamu-A*02 and the search model Mamu-A*01 were manually rebuilt in the COOT program under the guidance of F o Ϫ F c and 2F o Ϫ F c electron density maps (17) . Subsequently, we refined the initial rigid body and performed a series of restrained translation, libration, and screw-motion (TLS) refinements with the REFMAC5 program (50) . Additional rounds of refinements were performed using the phenix refine program implemented in the PHENIX package with isotropic ADP refinement and bulk solvent modeling (2) . We assessed the stereochemical quality of the final model with the PROCHECK program (32) .
The final model of Mamu-A*02/YY9 was subsequently used to determine the structure of Mamu-A*02/GY9 by molecular replacement, with three molecules presented in one Mamu-A*02/GY9 asymmetric unit. The same refinement steps were performed to generate the final model of Mamu-A*02/GY9. Crystallographic statistics for the final models of the two complexes are given in Table 1 . The molecular model and the electron density-related figures were generated using PyMOL (http://www.pymol.org/).
Protein structure accession numbers. The accession numbers of the structures of Mamu-A*02/YY9 and Mamu-A*02/GY9 in the Protein Data Bank are 3JTT and 3JTS, respectively. different domains (Fig. 1A) ; the ␣1 and ␣2 domains form a typical MHC molecule immunoglobulin domain, which contains two ␣-helices and eight ␤-sheets; the YY9 or GY9 peptide lies along the ␣-helices, which act as the edges of the peptide-binding groove; the ␣3 domain of Mamu-A*02 and ␤ 2 m (rhesus ␤ 2 m for Mamu-A*02/YY9 and human ␤ 2 m for Mamu-A*02/GY9) display typical immunoglobulin superfamily domains and underpin the ␣1 and ␣2 domains.
The overall structures of Mamu-A*02 are extremely similar to those of Mamu-A*01 (Fig. 1B) (13) . The superposition of Mamu-A*02/YY9 onto the previously determined structure of Mamu-A*01/CM9 generated a root mean square deviation (RMSD) of 0.72 Å. Moreover, the identity of the amino acid sequences of Mamu-A*02 and Mamu-A*01 is 89% (Fig. 2) . As expected, most of the polymorphic residues are located in the ␣1 and ␣2 domains. The ␣1 and ␣2 domains of Mamu-A*02 and Mamu-A*01 are also similar, with an RMSD of 0.61 Å. When we superimposed the ␣1 and ␣2 domains of Mamu-A*02 and Mamu-A*01, we found the most distinct portion of the two molecules to be located in the N terminus of the ␣2 helix, which covers residues 142 to 150 (Fig. 1C) . For Mamu-A*02/YY9, the ␣2 helix is closer to the ␣1 helix, which narrows the Mamu-A*02 peptide-binding groove. The alteration of the N terminus of the ␣2 helix is also found in the structure of human HLA-B*3501 compared to the closely related MHC allele HLA-A53 (66) and also occurs in HLA-A*1101 structures bound to different peptides (33) . In conjunction with the crystal lattice, the distinct C-terminal anchors of Mamu-A*02-and Mamu-A*01-bound peptides may also contribute to the substantial shift of ␣2 helix residues 142 to 150. Furthermore, our structural comparison highlights the altered solvent exposure of residues N142, R155, K156, A159, and A150 (for Mamu-A*02 versus Mamu-A*01), which may have important roles in the distinct MHC restrictions for T-cell receptor (TCR) recognition.
Conformations of the bound YY9 and GY9 peptides. The electron densities of the peptides in the structures of both Mamu-A*02 complexes clearly show the presenting conformations of the peptides ( Fig. 3A and B) . Both YY9 and GY9 are arched, and their N and C termini make tight contacts with the groove residues of Mamu-A*02. Thus, the central residues of the peptides are directed into the solvent and form few contacts with residues in the ␣1 and ␣2 domains of the Mamu-A*02 heavy chain.
The peptides of the three molecules in one asymmetric unit of the Mamu-A*02/YY9 complex exhibit the same conformation (Fig. 3C ). The RMSDs of the YY9 peptides from molecule 1 and molecule 2 superimposed onto molecule 3 are 0.23 Å and 0.18 Å, respectively. In contrast, the side chains of the central residues in peptide GY9 within the three molecules in one asymmetric unit of Mamu-A*02/GY9 deviate dramatically (Fig. 3D) . The RMSDs of GY9 from molecule 1 and molecule 2 compared to molecule 3 in the asymmetric unit of Mamu-A*02/GY9 are 0.47 Å and 0.51 Å, respectively. The solventexposed residues Asn4, Lys6, and Leu8 have flexible conformations. Notably, the side chain of the solvent-exposed Lys6 residue has very poor electron density, indicating the flexibility of this amino acid. Although the P1 and P2 anchors of GY9 have lower B factors than YY9, the higher B factors of the residues in middle region of GY9 ( Fig. 3C and D) indicate a more diverse TCR recognition mode for GY9 than for YY9.
When comparing the conformations of YY9 and GY9 by superimposing the ␣2 helix of Mamu-A*02, we found that the conformations of the main chains of the two peptides are different from each other, even though they are both nonamers ( Fig. 3E and F) . In the middle of the peptides, YY9 and GY9 have residues in different positions that are exposed to the solvent. At positions 7 and 8, YY9 has solvent-exposed Ile and Arg while GY9 has Ser and Leu, respectively. However, whereas YY9 has two glycines at positions 4 and 6, GY9 instead possesses Asn and Lys, which have much longer side chains. This makes the central region of GY9 much more exposed to the solvent, although this may not be the sole factor responsible for exposing the central region of GY9. When we aligned YY9 and GY9, we found that YY9 adopted a more extended conformation. We found the C␣ atom of Lys6 of GY9 to be raised 2.02 Å relative to the C␣ atom of Gly at the corresponding position of peptide YY9, indicating a larger bulge in the main chain of the middle portion of peptide GY9. The conformations of the C-terminal anchor Tyr9 of the two peptides also differed. There is a visible angle difference of 13.5°between the orientations of the two tyrosines of YY9 and GY9, also indicating that peptide YY9 is more extended.
Extremely flexible groove. Further analysis of the Mamu-A*02 structures indicated that the Mamu-A*02 residues in 
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the peptide-binding groove adopt a different conformation when accommodating peptide YY9 than when accommodating GY9 (Fig. 4A) . Residues Arg97, His114, Glu152, and His156 (Fig. 2) are conformationally shifted in the two structures. Compared to the Mamu-A*02/YY9 structure, the side chains of His114 and Glu152 in Mamu-A*02/GY9 are closer to the peptide and form additional hydrogen bonds with Glu3 and Ser7 in GY9, respectively. The residues in position 7 of YY9 (Ile) and GY9 (Ser) point toward different orientations due to this additional interaction of Glu152 with Ser7 of GY9. Consequently, GY9 presents an "M-shaped" conformation with a typical secondary anchor residue, while YY9 is presented in a flat manner. Moreover, GY9 carries the longer secondary anchors Glu and Leu in P3 and P7, respectively, where the presence of Glu3 in GY9 pushes the Mamu-A*02 His156 side chain away from the anchor compared to the structure of Mamu-A*02/YY9. The Arg97 side chain in Mamu-A*02/YY9 is also poked away from the side chain of Leu5 in GY9 due to a steric clash. All of these elements contribute to the distinct features of the binding of YY9 and GY9 to Mamu-A*02.
Variable C and D pockets. As mentioned above, the conformational differences between YY9 and GY9 are associated with the variable conformations of the residues constituting the bottom of the Mamu-A*02 peptide-binding groove. Further analysis indicated that the shapes and inner capacities of pockets C and D of Mamu-A*02 are also determined by these flexible residues (Fig. 4B and C) . For pocket C in Mamu-A*02/ GY9, Arg97 shifts to the C terminus of the peptide, which creates additional space to accommodate the secondary anchor Leu5 of GY9. For pocket D, the situation is more complicated. In the Mamu-A*02/GY9 structure, His114 is attracted to pocket D and forms a hydrogen bond with Glu3 of peptide GY9. In contrast, His156 is repelled from the pocket by the stereospecific blockage of the anchor Glu3 of GY9. In the case of Mamu-A*02/YY9, His114 possesses a different conformation and protrudes away from the D pocket. Further, His156 of Mamu-A*02/YY9 points to pocket D. However, we also observed some weak electron density for His156 of Mamu-A*02/YY9 in the same position as His156 of Mamu-A*02/GY9. This indicates that His156 is flexible when there is no steric hindrance from a large P3 Primary anchors of the bound peptides in pockets B and F. In the structures of both Mamu-A*02 complexes, a small B pocket and a large F pocket accommodate the primary anchor residues at position 2 of the N terminus and at the C terminus of the bound peptide, respectively (Fig. 5) . For YY9 and GY9, the P2 anchors are Thr and Ser, respectively, two of the most common P2 anchor residues in the Mamu-A*02 motif (40) . The small volume of the B pocket is formed by Tyr7, Tyr9, Glu63, Asn66, and Met67, which are conserved between Mamu-A*02 and Mamu-A*01 (Fig. 2 and 5A ). In the Mamu- A*02/YY9 and Mamu-A*02/GY9 structures, we found that the side chains of the P2 residues, Thr for YY9 and Ser for GY9, form similar hydrogen bonds with Glu63 and Asn66 (Fig. 5B) . These hydrogen bonds are also found in the structures of Mamu-A*01. These characteristics of the B pocket of Mamu-A*02 confirm the similar preference of Mamu-A*02 and Mamu-A*01 for small nucleophilic residues (e.g., Ser and Thr) as the P2 anchors.
With further structural analysis of Mamu-A*02, we found that a typical salt bridge is formed above the B pocket of Mamu-A*02 (Fig. 5A) . The salt bridge is composed of the negatively charged residue Glu163 and the positively charged residue Arg62. In the structure of Mamu-A*02/YY9, the P1 Tyr residue of YY9 protrudes out of the A pocket and pushes the salt bridge farther toward the C terminus of the peptide than the salt bridge in Mamu-A*02/GY9 (Fig. 4B and C) . The distance between the ε-C atoms of Arg62 is 3.73 Å. The distinctive salt bridge of Mamu-A*02 may help to stabilize the small P2 anchor in the B pocket.
Conserved residues (in the alignment of Mamu-A*02 with Mamu-A*01) Asn77, Tyr84, Tyr123, Thr143, Lys146, and Trp147, as well as the less conserved residues Asn80, Ile95, and Ser116, form the deep F pocket of Mamu-A*02, which accommodates the C-terminal anchor residue of the peptide (Fig. 2  and 5C ). Among these residues, the carboxyl groups of the YY9 and GY9 C termini form the two conserved hydrogen bonds with Tyr84 and Thr143 (Fig. 5D) . The less conserved residue Asn80 forms an additional hydrogen bond with the carboxyl group of the P9 anchor Tyr. This hydrogen bond, to the best of our knowledge, is not present in peptides bound to Mamu-A*01 (or other MHC I molecules). In the bottom of the F pocket, the Pc anchor Tyr forms a tight hydrogen bond with Ser116, which is also unique in both Mamu-A*02 structures. Compared to Mamu-A*01, Mamu-A*02 favors the large hydrophobic residue Tyr as the C-terminal anchor. From our structure analysis of Mamu-A*02, we found that two factors give the F pocket a larger capacity to accommodate this Tyr. First, residue 116 is smaller in Mamu-A*02 (Ser) than in (Fig. 6A) , with only nine variable residues. None of these nonconservative residues are located at the interface between ␤ 2 m and Mamu-A*02. Residues 31 to 34 and 52 to 60 of ␤ 2 m are the most important loops, which facilitate binding to the ␣1 and ␣2 domains of MHC I (1, 3, 14,  63) . Here, residues 31 to 34 and 52 to 60 remained the same, with RMSDs of 0.22 and 0.10 Å, respectively, between simian ␤ 2 m and human ␤ 2 m when binding to Mamu-A*02 (Fig. 6B) . The overall structures of the Mamu-A*02 ␣1 and ␣2 domains remained similar when binding to simian ␤ 2 m and human ␤ 2 m, as evidenced by the low RMSD of 0.40 Å obtained when we superimposed the Mamu-A*02 ␣1 and ␣2 domains of the two structures. These similarities indicate that the binding of human ␤ 2 m to Mamu-A*02 does not influence the peptide presentation of the Mamu-A*02 heavy chain. Moreover, the conformations of residues that play important roles in the binding of the coreceptor CD8 (11, 78) are similar for human ␤ 2 m and rhesus ␤ 2 m (data not shown).
DISCUSSION
SIV-specific CTL responses are exerted by short, virus-derived antigenic peptides that are presented by MHC molecules and are consequently recognized by TCRs (77) . Previous SIV T-cell immune studies have focused mainly on Mamu-A*01 ϩ rhesus macaques (8, 13, 76) . To date, Mamu-A*01 has been the only MHC from the nonhuman primate rhesus macaque whose structure was determined (13) . Mamu-A*02 is another prevalent rhesus macaque MHC allele found worldwide (4, 59) , and the disease progress of SIV infection and the specific T-cell responses in Mamu-A*02 monkeys are distinctive (4, 62) . Here we determined the structures of the rhesus macaque MHC I molecule Mamu-A*02 complexed with two typical SIV-derived immunogenic peptides. Our structural analyses demonstrated the peptide presentation characteristics of Mamu-A*02, which are beneficial for understanding SIV-specific T-cell immunity among Mamu-A*02 ϩ rhesus macaques. Generally, the P2 and Pc anchors of an MHC I binding peptide are restricted in an MHC allele-dependent manner, which is determined by the fixed conformations of the constitutive residues in the B and F pockets (45) . In contrast, it has been reported that the conformations of some residues within the C, D, and E pockets of the MHC peptide binding groove can be moderately tuned to accommodate peptides with different central residues (30, 42, 65, 67 ). For instance, in the conventional flexibility of the peptide-binding groove. Considering P3 residues, for instance, the D pocket of Mamu-A*02 can accommodate diverse residues, from small and hydrophobic (Ala) to large (Phe) and from positively charged (Arg) to negatively charged (Glu). This is in obvious contrast to the restricted selection for Pro in the P3 position of Mamu-A*01 (13) . Interestingly, according to a sequence analysis of MHC heavy chains from different species, the four flexible residues within the Mamu-A*02 groove are all located in nonconserved portions of the protein (Fig. 2) . Indeed, to the best of our knowledge, Mamu-A*02 is the only MHC molecule that possesses these four residues in their corresponding positions. These flexible residues in the peptide-binding groove contribute to the unique peptide presentation of Mamu-A*02.
Studies of CTL responses of structurally defined epitopes demonstrate that a rigid peptide conformation leads to a specific T-cell repertoire with limited diversity. In contrast, a diverse TCR repertoire is evoked by peptides with flexible, exposed residues (34, 37, 41) . A broader TCR repertoire specific to an MHC-peptide complex can limit the appearance of escape variants and maintain host resistance to the disease (46, 56, 64) . There is strong evidence that the immune escape mutants of YY9 occur in the early stage of SIV infection, while no GY9-derived mutants have been identified thus far (19, 52, 72) . The previous explanation of this phenomenon involved the different levels of fitness of the mutants (72) . However, the structural determination of YY9 and GY9 complexed with Mamu-A*02 led to a new hypothesis to explain this phenomenon (below). The GY9 peptide has two solvent-exposed residues (Asn4 and Arg6) in its central region, and furthermore, GY9 was revealed to be more flexible than YY9 when we superimposed the three molecules in one asymmetric unit of the two Mamu-A*02 structures. These structural differences in the presentation of the two peptides may lead to antigenic variance. It has been reported that GY9-specific T cells efficiently suppress SIV replication, while no suppression can be detected for YY9-specific T cells (58) . Although the YY9-specific TCR repertoire has been identified as a variable region beta (V␤) family usage (44) , and GY9-specific TCR usage has not been determined, we can rationally predict that the TCR repertoire specific for GY9 is relatively more diverse based on our structural analysis.
The appearance of CTL escape variants of SIV during chronic infection poses a challenge for host antivirus immunity. A series of mutants of peptide YY9 that often escape recognition by the initial YY9-specific CTL have been identified (19, 47, 51, 52, 72) . The frequently mutated positions occur at P3, P7, and P9 (19, 52, 72) . From the structure of Mamu-A*02/ YY9, the side chains of these three residues do not protrude into the solvent; therefore, they may not be recognized by TCRs directly. It has also been determined that the peptide binding affinities of the escape variants of YY9 are similar to those of YY9 (unless the C-terminal P9 anchor is mutated to residues other than Y and F). The substitution of residues in P3, P7, and P9 would therefore be rationally predicted to disrupt the presented conformation of YY9 by Mamu-A*02 (unpublished data). As seen in the structural comparison of Mamu-A*02/YY9 and Mamu-A*02/GY9, the flexible groove of Mamu-A*02 easily turns the main chain of the bound peptide into a distinct conformation when the groove-interactive residues of the peptide change. For the P7 residue of YY9-derived variants, the Ile residue tends to be replaced by Ser or Thr (19, 72) , which can form an additional hydrogen bond with Glu152 and lead to conformational rearrangement, as indicated in the Mamu-A*02/GY9 structure. The concordance between CTL escape and the conclusions of our structural analyses complement our findings on the peptide presentation of Mamu-A*02.
As elucidated in previous studies of MHC I molecule structures, the MHC heavy chain can be renatured in the presence of interspecies ␤ 2 m (1, 14, 34, 63) . Here our structural analysis of Mamu-A*02 complexed to rhesus macaque or human ␤ 2 m showed the interspecies heterocomplex to be similar to Mamu-A*02 folded with rhesus macaque ␤ 2 m (Fig. 6) . The conserved sequences and their similar conformations within the heavy chain-␤ 2 m interface indicate that the peptide presentation of Mamu-A*02 is not affected by the alteration of ␤ 2 m from rhesus to human ␤ 2 m (1, 63) .
The elucidation of peptide presentation characteristics of Mamu-A*02 via structural determination increases our understanding of anti-SIV T-cell responses, including confirmation of the antigenic peptide motif, evidence of peptide immunodominance (38) , and insights into CTL escape. Moreover, these findings also provide beneficial reference points for the extrapolation of the T-cell studies from rhesus macaques to humans.
